Illumina (ILMN) shares are soaring 5.05% in Wednesday's intraday trading following the company's announcement of a new business initiative called BioInsight. This strategic move has sparked investor interest, driving the stock to significant gains.

BioInsight is set to focus on developing data assets, software, and artificial intelligence tools to provide deeper biological insights for life sciences research and development. The new business aims to enable large-scale genetic and biological data generation projects, develop software for multimodal data analysis, and create AI tools to facilitate extensive multimodal data analysis.

This launch aligns with the increasing industry demand for deeper biological insights and is expected to drive Illumina's long-term growth. By expanding access to omics data for target discovery and drug development, Illumina positions itself at the forefront of technology and data-driven discovery in the life sciences sector. The market's positive reaction suggests that investors see significant potential in this new venture to enhance Illumina's competitive edge and future revenue streams.